RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:
Michael Gemellaro, CPA, MST’s Post
More Relevant Posts
-
Recent transactions may indicate an opening in the biotech IPO market. This and more in this week’s life sciences update. https://rsm.buzz/4do0toA
-
-
RSM’s Robert Zonenshein critiques retroactive tax regulations in New York state, urging businesses to consider proactive steps to address risk. https://rsm.buzz/4gkmR4H
-
-
As a forward-thinking tax professional, you understand that staying ahead in global tax policy isn’t just about today—it’s about the future. Join our forum to explore cutting-edge strategies and technologies that will shape the next era of international tax. https://rsm.buzz/4ecJC8Q
-
-
RSM did it again! My firm made the PEOPLE Companies That Care® list for the fourth consecutive year. Learn more: https://rsm.buzz/3AT5mIp
-
-
Senior-level biopharma professionals are increasingly opting for fractional roles where they work part time for companies. This and more in this week's update. https://rsm.buzz/3XtiDjJ
-
-
With deal volumes projected to increase, buyers and sellers must contend with the risk of post-closing disputes, and the high-stakes dispute resolution process that goes with it. Here are a few post-acquisition dispute trends we are seeing and expect going forward. https://rsm.buzz/4e21wuW
-
-
The medtech sector sees renewed IPO and acquisition activity. This and more in this week’s life sciences update. https://rsm.buzz/3MooznO
-